Organogenesis (NASDAQ:ORGO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Organogenesis (NASDAQ:ORGO) from a hold rating to a buy rating in a research report released on Sunday.

Other analysts have also recently issued reports about the company. BTIG Research dropped their price target on shares of Organogenesis from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, February 27th. Weiss Ratings raised shares of Organogenesis from a “sell (d+)” rating to a “hold (c)” rating in a research report on Friday, February 27th. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

Organogenesis Price Performance

ORGO opened at $2.71 on Friday. The firm has a market cap of $348.61 million, a price-to-earnings ratio of 33.88 and a beta of 1.43. Organogenesis has a 12-month low of $2.61 and a 12-month high of $7.08. The company has a current ratio of 3.62, a quick ratio of 3.32 and a debt-to-equity ratio of 0.04. The stock’s 50-day moving average price is $3.84 and its 200 day moving average price is $4.49.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.10. Organogenesis had a return on equity of 21.41% and a net margin of 5.32%.The business had revenue of $225.61 million during the quarter, compared to analysts’ expectations of $172.68 million. As a group, sell-side analysts expect that Organogenesis will post -0.07 earnings per share for the current year.

Insiders Place Their Bets

In other Organogenesis news, Director Glenn H. Nussdorf sold 200,000 shares of the company’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $5.14, for a total transaction of $1,028,000.00. Following the transaction, the director directly owned 2,565,591 shares in the company, valued at approximately $13,187,137.74. This represents a 7.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 33.00% of the stock is owned by corporate insiders.

Institutional Trading of Organogenesis

Large investors have recently bought and sold shares of the company. State of Alaska Department of Revenue purchased a new stake in shares of Organogenesis in the third quarter valued at about $25,000. Quarry LP acquired a new position in shares of Organogenesis during the 3rd quarter worth approximately $25,000. Flagship Harbor Advisors LLC acquired a new position in shares of Organogenesis during the 4th quarter worth approximately $34,000. Federated Hermes Inc. lifted its stake in Organogenesis by 52.8% in the 4th quarter. Federated Hermes Inc. now owns 8,541 shares of the company’s stock valued at $44,000 after buying an additional 2,953 shares in the last quarter. Finally, Walleye Capital LLC acquired a new stake in Organogenesis during the 2nd quarter valued at $45,000. Institutional investors and hedge funds own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.